Skip to main content

Eosinophilic Asthma Treatment Market Set to Witness an Uptick During 2016 - 2024 -Persistence Market Research

Press Release   •   Feb 28, 2017 05:13 EST

Eosinophilic asthma is a form of asthma categorized by greater levels of eosinophils in the air passages. Eosinophilic asthma includes contraction and inflammation of the air passages that makes breathing very difficult. Various symptoms are observed in eosinophilic asthma. The symptoms of eosinophilic asthma can be treated by many asthma medications like bronchodilators, anti-inflammatories and asthma inhaling systems. Eosinophilic asthma treatment includes:

  • The allergens can be avoided like certain medications ,smoking, pollens or dust which may cause eosinophilic asthma
  • Bronchodilators, antihistamines, corticosteroids and anti-inflammatories can be used as medication
  • Corticosteroids, leukotriene modifiers, Nedocromil, Theophylline, long-acting beta-2 agonists act as long term Eosinophilic asthma controller.

The active sputum is mostly considered a reliable source for inflammatory cell counts though quantitative analysis of sputum is difficult to obtain in daily practice and also requires access to particular laboratories with trained staff. Several alternative markers of Eosinophilic inflammation are presently being checked like fractional exhaled nitric oxide (FeNO), periostin levels, peripheral blood eosinophil counts and serum IgE.

Request to View Tables of Content @

Eosinophilic Asthma Treatment market is driven by increasing pollution and lowering immunity in the population. Susceptibility of allergies within individuals has increased resulting in the increased incidences of eosinophilic asthma. The rise in the new biologic treatments, including monoclonal antibodies and small molecule inhibitors targeted against IgE, Th2 cytokines, and specific inflammatory mediators, has led to an enhanced understanding of the pathogenesis of asthma and highlighted the importance of patient-specific treatment leading to a rise in eosinophilic asthma treatment market. Major restraining factors in the eosinophilic asthma treatment factor can be the regulatory policies of individual regions regarding the acceptance of new biologic therapies for eosinophilic asthma.

Global Eosinophilic Asthma Treatment Market: Segmentation

On the basis of Route of Administration, the Global Eosinophilic Asthma Treatment market can be segmented into,

  • Oral
  • Rectal
  • Intravenous
  • Nasal

On the basis of type of medication, the Global Eosinophilic Asthma Treatment market can be segmented into,

  • Long term control medications
  • Short acting medications
  • Biologic therapies

On the basis of Region, the Global Eosinophilic Asthma Treatment market can be segmented into,

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

The Global Eosinophilic Asthma Treatment market on the basis of route of administration can be segmented on the basis of orally, rectally, intravenously and nasally. Long term control medications are inhaled corticosteroids leukotriene modifiers, long-acting beta agonists (labas) and theophylline and combination inhalers that contain both a corticosteroid and a laba. Short term control medications are short-acting beta agonists like (proair hfa, ventolin hfa, others) and levalbuterol (xopenex), ipratropium (atrovent) and oral and intravenous corticosteroids.

From the global perspective, North America accounts for the largest market share for eosinophilic asthma treatment market owing to the rising demand of asthma lowering drugs owing to the increasing incidences of allergens causing the eosinophilic asthma. High adoption rate of eosinophilic asthma treatment in North America probably will help the region to retain the position of the leading region in the forecast years. However, other regions like Latin America, Asia Pacific, and Europe are expected to be probable markets in coming years. Across emerging markets, Latin America and Asia Pacific, the eosinophilic asthma treatment market is expected to have a strong growth in the forecast years. Due to the extensive awareness about the eosinophilic asthma treatment, these areas are most likely to be potential markets for eosinophilic asthma treatment.

Buy Now: You can now buy a single user license of the report at The final report customized as per your specific requirement will be sent to your e-mail id within 7-20 days, depending on the scope of the report.

Currently, the global eosinophilic treatment market is highly competitive owing to the involvement of many established players. Some of the key players in the eosinophilic treatment market are. Johnson & Johnson, Novartis, Roche, Pfizer, Sanofi, Merck, GlaxoSmithKline, AstraZeneca, Bayer and Gilead.

For more information, please e-mail us at

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City, 

NY 10007, United States,

USA - Canada Toll Free: 800-961-0353



Comments (0)

Add comment